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Abstract
Introduction Breast cancer is the most common type of cancer
seen in women in western countries. Thus, diagnostic modalities
sensitive to early-stage breast cancer are needed. Antibody-
based array platforms of a data-driven type, which are expected
to facilitate more rapid and sensitive detection of novel
biomarkers, have emerged as a direct, rapid means for profiling
cancer-specific signatures using small samples. In line with this
concept, our group constructed an antibody bead array panel
for 35 analytes that were selected during the discovery step.
This study was aimed at testing the performance of this 35-plex
array panel in profiling signatures specific for primary non-
metastatic breast cancer and validating its diagnostic utility in
this independent population.
Methods Thirty-five analytes were selected from more than 50
markers through screening steps using a serum bank consisting
of 4,500 samples from various types of cancer. An antibody-
bead array of 35 markers was constructed using the Luminex™
bead array platform. A study population consisting of 98 breast
cancer patients and 96 normal subjects was analysed using this
panel. Multivariate classification algorithms were used to find
discriminating biomarkers and validated with another
independent population of 90 breast cancer and 79 healthy
controls.
Results Serum concentrations of epidermal growth factor,
soluble CD40-ligand and proapolipoprotein A1 were increased
in breast cancer patients. High-molecular-weight-kininogen,
apolipoprotein A1, soluble vascular cell adhesion molecule-1,
plasminogen activator inhibitor-1, vitamin-D binding protein and
vitronectin were decreased in the cancer group. Multivariate
classification algorithms distinguished breast cancer patients
from the normal population with high accuracy (91.8% with
random forest, 91.5% with support vector machine, 87.6% with
linear discriminant analysis). Combinatorial markers also
detected breast cancer at an early stage with greater sensitivity.
Conclusions The current study demonstrated the usefulness of
the antibody-bead array approach in finding signatures specific
for primary non-metastatic breast cancer and illustrated the
potential for early, high sensitivity detection of breast cancer.
Further validation is required before array-based technology is
used routinely for early detection of breast cancer.
2D-PAGE: two-dimensional polyacrylamide gel electrophoresis; A1AT: alpha-1 antitrypsin; A2M: alpha-2 macroglobulin; AFP: alpha-fetoprotein; Apo: 
apolipoprotein; AUC: area under the curve; BSA: bovine serum albumin; CA: cancer antigen; CAM: cell adhesion molecules; CEA: carcinoembryonic 
antigen; CRP: C-reactive protein; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbent assay; HDL: high-density lipoprotein; HER: 
human epidermal growth factor receptor; HMWK: high-molecular-weight kininogen; HSP: heat shock protein; IL: interleukin; LDA: linear discriminant 
analysis; MALDI: matrix-assisted laser desorption/ionisation; MPO: myeloperoxidase; MS: mass spectrometry; PAI-1: plasminogen activator inhibitor-
1; PBS: phosphate-buffered saline; PCA: principal component analysis; ProApo: proapolipoprotein; PSA: prostate specific antigen; RF: random for-
ests; ROC: receiver operating curve; SAA: serum amyloid A; sCD40L: soluble CD-40 ligand; SELDI-TOF: surface-enhanced laser desorption/ioni-
sation time-of-flight; sICAM-1: soluble intercellular adhesion molecule-1; sVCAM-1: soluble vascular cell adhesion molecule-1; SVM: support vector 
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Introduction
Breast cancer is the most common malignant disease in
women in western countries, comprising approximately 35%
of all cancers [1]. The incidence of breast cancer has
increased over the past few decades, probably due to earlier
diagnosis, and mortality has been gradually reducing [2].
Nonetheless, prevention and early detection of breast cancer
are two major issues of consideration for cancer epidemiolo-
gists and clinicians because radical treatment can greatly
reduce breast cancer-related mortality if breast cancer is
detected at an early stage [3]. Despite the use of mammogra-
phy as a routine screening method for women 40 years of age
and older, the effectiveness of this procedure in reducing over-
all population mortality is still being investigated [4]. Other
diagnostic modalities that can improve diagnostic power in
combination with conventional methods are required for stra-
tegic management of the disease and improvement of the
overall mortality rate.
Biomarker research in easy-to-access biological fluids from
cancer patients is expected to open up a new era in the field
of cancer research and cancer diagnostics. Extensive
searches have revealed several breast cancer-specific mark-
ers: MUC-1 family mucin glucoproteins like CA 15.3, BR27.29
(or CA27.29), and mucin-like carcinoma-associated antigen,
CA 549, carcinoembryonic antigen (CEA), serum human epi-
dermal growth factor receptor (HER) 2/c-erbB-2, cytokines
and cytokeratin fragments [5-10]. Although these markers are
not used for the purposes of screening and early diagnosis,
they play a complementary role in staging work-up at initial
presentation as indicated in the guidelines issued by the Euro-
pean Group on Tumor Markers (EGTM) [11] and the Food and
Drug Administration [12].
Recent advancements in high-throughput platforms and infor-
mation technology have ushered in the data-driven approach,
which has emerged as a powerful and efficient way of con-
ducting biomarker research and finding novel biomarkers. In
the field of proteomics, the classical approach uses two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE)
for comparing multiple protein profiles. However, this method
has problems such as poor reproducibility and low throughput.
Recent advances in mass spectrometry (MS), such as matrix-
assisted laser desorption/ionisation (MALDI) time-of-flight MS,
offer an alternative to 2D-PAGE [13]. However, some limita-
tions in MALDI, such as extensive sample preparation and high
signal background problems resulting from inorganic and
organic contaminants, have hindered its wider use as a high-
throughput screening tool to find useful proteins in complex
biological samples. The development of surface-enhanced
laser desorption/ionisation time-of-flight (SELDI-TOF) MS has
largely overcome these limitations [14]. In the field of breast
cancer research, Li and colleagues performed a pioneering
study using SELDI-TOF and found potential biomarkers for
detection of breast cancer, designating the peaks as BC1 (4.3
kDa), BC2 (8.1 kDa) and BC3 (8.9 kDa) [15]. Later, some of
these were identified as fragments of serum complement pro-
tein, but these results are awaiting further validation.
Antibody-based microarray is also one of the data-driven
approaches in proteomics that is likely to play an increasing
role in the discovery of disease-specific signatures [16]. The
spectrum of chemical biomarker information that can be eluci-
dated using this method is relatively limited compared with
that obtained using MS. However, the antibody-array platform
bypasses the identification step for individual markers, making
this a faster and more direct method for profiling protein
expression and translating this information [17,18]. Further-
more, a combinatory strategy for utilising markers and statis-
tics has been suggested to increase predictive power in
cancer diagnosis, which re-energises the search for novel can-
cer-related biomarker signatures [19,20].
In line with this concept, Carlsson and colleagues adopted a
planar array platform using single-chain variable fragment
(scFv) targeting for more than 60 target antigens and found a
serum protein signature that distinguishes breast cancer
patients from normal subjects with high diagnostic accuracy
[21]. Recently, the bead-array platform was also successfully
applied to identify serum profiles predicting responses to neo-
adjuvant chemotherapy in locally advanced breast cancer
[22].
Recently, our group constructed an antibody-based bead
array panel consisting of 35 serum proteins via an extensive
screening process using 4500 serum samples from various
cancer patients. We report the characteristic serum profiles
associated with breast cancer as revealed by application of
this panel in an independent group of patients with mostly pri-
mary, non-metastatic disease and validate the diagnostic per-
formance of these combinatorial markers.
Materials and methods
Study samples
Two sets of population were constructed. A training set (set 1)
for selecting prediction biomarkers consisted of 194 people
(98 breast cancer patients and 96 normal controls). The other
independent set (set 2), consisting of 169 people (90 breast
cancer patients and 79 normal controls), was used for valida-
tion of selected predictors from the initial set. In each set, can-
cer and control populations were age-matched. Serum
samples of breast cancer patients were obtained before any
type of surgical procedures. None of the patients had a family
history of breast cancer. Serum samples for the controls were
obtained from normal female subjects who voluntarily enrolled
in the cancer screening program of Seoul National University
Hospital and had no abnormalities identified on physical exam-
ination, routine blood testing or mammography. A complete
medical history was obtained for each patient, including med-
ication, menstrual history, menopause, alcohol consumptionAvailable online http://breast-cancer-research.com/content/11/2/R22
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and smoking. All blood samples were collected before any
type of surgical or medical intervention was performed. Periph-
eral blood was collected using 5 ml syringes and stored in
SST™ II tubes (Becton Dickinson, Franklin Lakes, NJ, USA) at
room temperature for one hour. Samples were centrifuged at
3000 g for five minutes, and the supernatants were collected
and stored at -80°C before the assay was performed. Samples
were drawn after obtaining informed consent from all patients.
The study protocol was reviewed and approved by Institutional
Review Board at Seoul National University Hospital (approval
No. C-0512-502-163).
Construction of 35-plex bead array panel
The antigen panel consisted of 35 analytes (Table 1). Thirty-
five markers were chosen from 51 original markers (Figure 1).
A serum bank had been constructed for determination of can-
cer biomarkers. The serum bank contained approximately
4500 samples from five types of cancer: breast, colon, stom-
ach, liver and lung. Alpha-1-antitrypin, pro-apolipoprotein
(proApo) A1, apolipoprotein (Apo) A4, haptoglobin α, and
transthyretin were discovered using 2D-PAGE. ApoH, β2-
microglobulin, vitamin D-binding protein, C-reactive protein
(CRP), free haemoglobin and serum amyloid A were discov-
ered using SELDI-TOF MS. These 11 markers were regarded
as candidate markers with 40 markers selected through a lit-
erature search. The list of 51 candidate markers at this stage
was as follows: adiponectin, alpha-2 macroglobulin (A2M),
alpha-fetoprotein (AFP), alpha-1 antitrypsin (A1AT), ApoA1,
proApoA1, ApoA2, ApoA4, ApoC2, ApoC3, ApoH, ApoJ
(clusterin), beta-2 microglobulin, ferritin, CA-125, CA19-9,
CA72-4, CEA, cathepsin B, chromogranin A, CRP, D-dimer,
epidermal growth factor (EGF), galectin 3, gelsolin, hap-
toglobin alpha, total haptoglobin, free haemoglobin, heat
shock protein (HSP) 27, HSP 70, high-molecular-weight
kininogen (HMWK), human cervical cancer oncogene-1, IL-1
beta, IL-1 receptor alpha, IL-6, IL-8, monocyte chemoattract-
ant protein-1, macrophage inflammatory protein-1, myeloper-
oxidase (MPO), neuron specific enolase, retinol binding
protein 4, total plasminogen activator inhibitor (PAI)-1, total
prostate specific antigen (PSA), free PSA, pro-gastrin releas-
ing peptide, soluble CD-40 ligand (sCD40L), soluble intercel-
lular adhesion molecule (sICAM)-1, soluble vascular cell
adhesion molecule (sVCAM)-1, serum amyloid A (SAA), tran-
sthyretin, vitamin-D binding protein (VDBP) and vitronectin.
The sandwich ELISA method for individual analytes was used
as a validation method, again using samples from the serum
bank. Markers with significantly different mean serum concen-
trations in cancer patients and normal subjects were selected
and subjected to the 35-plex bead array panel.
Bead array kits or antibodies for the construction of the 35-
plex panel were purchased from the following manufacturers:
Abcam (Cambridge, UK), Bethyl (Montgomery, TX, USA),
Biodesign International (Saco, ME, USA), BoditechMed
(Chuncheon, Korea), Chemicon (Temecula, CA, USA), Dako
(Glostrup, Denmark), EMD Chemicals Inc. (San Diego, CA,
USA), Fitzgerald (Concord, MA, USA), HyTest (Turku, Fin-
land), Linco Research, Inc. (St. Charles, MO, USA), Rules-
based Medicine (Austin, TX, USA), R&D Systems (Minneapo-
lis, MN, USA), Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA), Sigma-Aldrich (St Louis, MO, USA) and US Biological
(Swampscott, MA, USA).
Figure 1
Procedure for constructing the 35-plex panel Procedure for constructing the 35-plex panel. Through using 4500 serum samples from cancer patients, five markers were discovered and identified 
through two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), six markers through surface-enhanced laser desorption/ionisation time-of-
flight (SELDI-TOF) and 24 markers through conventional sandwich ELISA method. After optimisation in capturing and detecting the antibody pair for 
a target analyte, the capturing antibody was conjugated with beads, and the simplex kit was validated for its dynamic range, recovery rate, parallelism 
with standard curve, interference, matrix effect, and lower and upper limits of detection. Twenty-three simplex kits could be grouped together accord-
ing to dilution factor and absence of cross reactivity. The remaining 12 were left and used as a simplex kit. BC = breast cancer; SC = stomach can-
cer; LC = lung cancer; CC = colon cancer; HCC = hepatocellular carcinoma.Breast Cancer Research    Vol 11 No 2    Kim et al.
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Multiplex assay procedure
Multiplex assay was performed using the following procedure:
a 96-well filter-plate (Millipore, Billerica, MA, USA) was
blocked with PBS (pH 7.4) with 2% BSA. Twenty microliters
of standard curve sample, prediluted control samples and
patient samples were dispensed into the wells in duplicate.
Twenty microliters of primary antibody-bead mixture were
added into each well and incubated at room temperature for
one hour. Twenty microliters of detection antibodies with bioti-
nylation and 20 μL of streptavidin-phycoerythrin were added
and incubated at room temperature for one hour. Each step
was followed by a double washing step using 0.05% Tween-
20 in PBS (PBST) with vacuum manifold (Millipore Corp., Bill-
erica, MA, USA).
After the final washing step, samples were resuspended with
100 μL of PBST and read using a Luminex-200™ (Luminex
Inc., Austin, TX, USA). The standard curve was calculated
using five-parametric-curve fitting, and results were analysed
using Beadview software (Upstate Biotechnology Inc., Lake
Placid, NY, USA). Markers were grouped together according
to dilution factor after cross-reactivity was checked across all
analytes. Control samples at two levels in the dynamic range
of the standard curve were run together in duplicate for quality
control throughout the study. Intra-assay precision ranged
from 2 to 16%, and inter-assay precision ranged from 6 to
19% during the experiment. The acceptance criteria for each
individual run followed Westgard's rule [23].
Table 1
List of biomarkers in 35-plex panel
Marker list
Oncofetal protein Acute phase protein
Alpha-fetoprotein (AFP) Alpha-1-antitrypin (A1AT)a
Carcinoembryonic antigen (CEA) Alpha-2 macroglobulin (A2M)c
Cancer antigen 125 (CA125)c C-reactive protein (CRP)b
Cancer antigen 19-9 (CA19-9)c D-dimer (DD)c
Prostate-specific antigen (PSA)c Haptoglobin α (Hp)a
Cytokine Serum amyloid A (SAA)b
Interleukin-1β (IL-1β)c Transthyretin (TTR)a
Interleukin-1 receptor α (IL-Rα)c Coagulation/thrombosis
Interleukin-6 (IL-6)c Haemoglobin (Hg)b
Interleukin-8 (IL-8)c High-molecular-weight kininogen (HMWK)c
Monocyte chemotactic protein-1
(MCP-1)c
Plasminogen activator inhibitor-1
(PAI-1)c
Monocyte inflammatory protein-1α (MIP-1α)c Metabolism
Immune/inflammation Apolipoprotein A1 (ApoA1)c
Soluble CD40 ligand (sCD40L)c Pro-apolipoprotein A1 (proApoA1)a
β2-microglobulin (β 2M)b Apolipoprotein A4 (ApoA4)a
Myeloperoxidase (MPO)c Apolipoprotein H (ApoH)b
Factor/hormone Carrier
Epidermal growth factor (EGF)c Vitamin D-binding protein (VDBP)b
Adiponectinc Enzyme
Adhesion Cathepsin B (CB)c
Vitronectin (VN)c
Soluble vascular cell adhesion molecule-1 (sVCAM-1)c
Soluble intercellular cell adhesion molecule-1 (sICAM-1)c
aMarkers were discovered through two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) using the serum of breast cancer patients. 
bMarkers were discovered through surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) mass spectrometry. cMarkers were 
selected using literature search.Available online http://breast-cancer-research.com/content/11/2/R22
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Bioinformatics and statistics
The values of markers were transformed into log values before
analysis using a multivariate classification algorithm. As an ini-
tial step, principal component analysis (PCA) was performed
using information related to the concentration of all 35 mark-
ers, in order to study clustering of breast cancer and normal
subjects. Random forest (RF), support vector machine (SVM)
and linear discriminant analysis (LDA) were the multivariate
algorithms used. Among the 196 cases, two-thirds of the
cases from the breast cancer and normal groups were ran-
domly assigned to training sets, and the remaining one-third
were assigned to test sets. We compared the prediction per-
formances obtained from 50 randomly partitioned data sets.
Classification models with selected predictors obtained from
the experiment with set 1 were validated again with set 2. A
receiver operating characteristic (ROC) curve was con-
structed, and the area under the curve (AUC) was calculated
using each algorithm. We extracted a classifier consisting of a
subset of protein markers yielding the best classification per-
formance in the test sets. A student's t-test (two-sided) was
performed to compare the mean serum marker levels among
groups stratified by clinical and pathological variables, and
Pearson's correlation was performed to compare maximum
tumour length and number of lymph node metastases with
serum biomarker levels. All calculations were performed using
the R program package (Wirtschafts universität, Wien, Aus-
tria) [24].
Results
Analysis of differentially expressed serum makers in 
patients with breast cancer and in normal subjects
The mean serum concentrations for individual analytes were
compared between patients with breast cancer and those
without breast cancer. Among the 35 analytes, EGF, sCD40L
and proApoA1 showed higher serum concentrations in breast
cancer patients than in normal subjects (Table 2). HMWK,
ApoA1, PAI-1, VDBP and vitronectin levels were significantly
decreased in cancer patients. EGF showed the highest AUC
value (0.89) and exhibited a diagnostic accuracy of 82.3%,
sensitivity of 94.0% and specificity of 70.6% as a single
marker.
Multivariate classification using combinatorial 
biomarkers specific for breast cancer
In order to geometrically interpret and determine if breast can-
cer patients could be segregated from normal subjects, PCA
analysis was performed using all the data related to serum lev-
els of the 35 markers. Principal components deduced from
variance-covariance structures of these markers separated
these two groups using the top two principal components
(Figure 2a). In order to find classifiers that distinguish breast
cancer patients from healthy people, multivariate classification
analysis was performed using RF, SVM and LDA. In the inter-
est of constructing models and selecting predictors, two-
thirds of the original set was assigned to training sets. After
training, each model consisting of different sets of classifiers
was validated through the test set. The accuracy and classifi-
cation error for each model were calculated in each training
and test set. The calculated averages are summarised in Table
3. RF, SVM and LDA classified breast cancer and normal sub-
jects with a mean accuracy of 91.8%, 91.5% and 87.6%,
respectively. For the validation of this model, an independent
validation set consisting of 169 persons was analysed using
the same model and predictors. The calculated averages were
similar to those obtained from the original set (Table 3). The
combination of markers showing the highest diagnostic accu-
racy was very similar in all three models. EGF, sCD40L,
HMWK, ApoA1, PAI-1 and VDBP were consistently selected
by all three algorithms. D-dimer and vitronectin were chosen
by RF and SVM. Pre-treatment serum levels of CA15-3 were
available in 96 patients, and serum levels of tissue polypeptide
antigen were available in 77 patients. When the sensitivity of
combinatorial markers was compared with that of single mark-
ers, multi-classifiers showed improvement not only in overall
sensitivity for total patients but also in sensitivity for early-stage
disease (Table 4).
Comparison of biomarkers with clinico-pathological 
parameters of breast cancer
All clinical and pathological factors were analysed and com-
pared with serum concentrations of the 35 analytes (Table 5).
Advanced T-stage breast cancer (T3 and T4) showed
increased serum levels of EGF and ApoH, but decreased lev-
els of A1AT. Patients with lymph node metastasis showed
increased serum concentrations of sVCAM-1 and transthyre-
tin. The number of lymph node metastases was positively cor-
related with sVCAM-1 and D-dimer (Pearson's correlation
coefficient = 0.23, P = 0.025; and Pearson's correlation coef-
ficient = 0.25, P = 0.028, respectively). Patients with distant
metastasis showed lower levels of proApoA1 in the serum.
The expression status of oestrogen receptor, progesterone
receptor and c-erbB2 in tumour tissue was also reflected in
serum levels of analytes. In oestrogen receptor-positive
patients, serum levels of A2M and HMWK were increased,
and concentrations of vitronectin, transthyretin and PAI-1 were
decreased. Higher serum levels of A2M and CA19-9 were
observed in progesterone receptor-positive patients. In
patients showing c-erbB2 expression in tumour tissue, serum
levels of sVCAM-1 were decreased, whereas SAA levels were
increased. No correlation was noted between the serum EGF
level and c-erbB2 expression (c-erbB2 positive = 324 ±
203.58 pg/ml, vs. c-erbB2 negative = 319.39 ± 209.47 pg/
ml, P = 0.908). The serum concentration of 35 analytes was
not influenced by factors such as nuclear grade, histological
grade, location or multiplicity of tumour mass.Breast Cancer Research    Vol 11 No 2    Kim et al.
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Table 2
Summary of differentially expressed serum markers between breast cancer and control subjects
Marker Breast cancer
(Mean ± SD)
Normal
(Mean ± SD)
P valuea AUC
EGF (pg/ml) 325.14 ± 208.39 76.67 ± 71.42
sCD40L (pg/ml) 11226.31 ± 71363.00 32.17 ± 30.35 < 0.001 0.85
HMWK (ug/ml) 19.65 ± 13.49 33.98 ± 15.15 < 0.001 0.76
ApoA1 (ng/ml) 224.36 ± 94.02 322.70 ± 136.80 < 0.001 0.72
sVCAM-1 (ng/ml) 728.05 ± 170.55 832.57 ± 162.23 < 0.001 0.69
PAI-1 (ng/ml) 18.97 ± 6.51 23.38 ± 9.25 < 0.001 0.65
ProApoA1 (ng/ml) 26.74 ± 9823.61 22.14 ± 8.21 < 0.001 0.65
VDBP (ng/ml) 173.65 ± 36.15 191.63 ± 43.57 < 0.001 0.65
VN (ng/ml) 4848.98 ± 2626.57 5546.35 ± 2168.00 0.001 0.64
D-dimer (ng/ml) 1249.58 ± 259.30 539.70 ± 417.99 0.0340 0.59
A1AT (ng/ml) 3594.23 ± 5875.33 3143.05 ± 16616.57 0.808 0.51
CRP (ng/ml) 5154.88 ± 39551.30 2860.52 ± 16501.80 0.818 0.51
AFP (ng/ml) 0.81 ± 0.49 0.76 ± 0.53 0.376 0.54
CEA (ng/ml) 12.36 ± 8.75 10.24 ± 5.11 0.144 0.56
PSA (ng/ml) 0.02 ± 0.05 0.02 ± 0.1 0.750 0.51
CA125 (U/ml) 16.76 ± 71.52 4.91 ± 5.71 0.465 0.53
CA19-9 (U/ml) 60.17 ± 151.07 25.02 ± 20.67 0.016 0.60
B2M (ng/ml) 692.36 ± 166.13 720.68 ± 162.14 0.125 0.56
A2M (ng/ml) 74.00 ± 28.05 85.03 ± 34.28 0.010 0.61
Adiponectin (ng/ml) 12802.04 ± 10393.99 14358.12 ± 6563.28 0.014 0.60
MPO (pg/ml) 146459.9 ± 142930.01 112079.27 ± 100310.31 0.233 0.55
sICAM-1 (ng/ml) 162.31 ± 43.77 173.87 ± 57.84 0.171 0.56
IL-1β (pg/ml) 4.06 ± 11.12 2.74 ± 4.2 0.790 0.51
IL-1Rα (pg/ml) 269.47 ± 361.27 155.37 ± 207.52 0.008 0.61
IL-6 (pg/ml) 36.66 ± 94.93 33.27 ± 75.37 0.720 0.51
IL-8 (pg/ml) 450.89 ± 2970.97 24.24 ± 45.59 0.424 0.53
MCP-1 (pg/ml) 273.38 ± 312.79 280.57 ± 103.93 0.015 0.60
MIP-1α (pg/ml) 76.44 ± 225.17 56.39 ± 88.25 0.224 0.55
ApoA4 (ng/ml) 10382.14 ± 3924.34 10742.81 ± 3755.76 0.544 0.53
TTR (ng/ml) 177.40 ± 58.38 198.27 ± 65.85 0.029 0.59
Hp (ng/ml) 1080.38 ± 662.48 921.74 ± 448.23 0.197 0.55
SAA (ng/ml) 4261.8 ± 9028.56 2872.43 ± 5133.39 0.155 0.56
Hg (ng/ml) 249.95 ± 100.58 82 ± 44.23 < 0.001 0.66
CB (ng/ml) 943.79 ± 110.01 1081.19 ± 847.39 0.003 0.62
ApoH (ng/ml) 125.67 ± 131.69 128.54 ± 31.32 0.520 0.53
aSpecific false discovery rate at a 1% level.
A1AT = alpha-1 antitrypsin; A2M = alpha-2 macroglobulin; AFP = alpha-fetoprotein; Apo = apolipoprotein; AUC = area under the curve; B2M = 
beta-2 macroglobulin; CA = cancer antigen; CB = cathepsin B; CEA = carcinoembryonic antigen; CRP = C-reactive protein; EGF = epidermal 
growth factor; Hg = haemoglobin; HMWK = high-molecular-weight kininogen; Hp = haptoglobin; IL = interleukin; MCP = monocyte chemotactic 
protein; MIP = monocyte inflammatory protein; MPO = myeloperoxidase; PAI = plasminogen activator inhibitor; ProApo = proapolipoprotein; PSA 
= prostate specific antigen; SAA = serum amyloid A; sCD40L = soluble CD-40 ligand; SD = standard deviation; ICAM = intercellular adhesion 
molecule; sVCAM = soluble vascular cell adhesion molecule; TTR = transthyretin;VDBP = vitamin-D binding protein; VN = vitronectin.Available online http://breast-cancer-research.com/content/11/2/R22
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Discussion
Implications and limitations of the present study using 
an antibody-bead array platform for breast cancer 
proteomics
Breast cancer is a global issue in that it is the most frequently
diagnosed cancer and the leading cause of cancer death
among women worldwide [25]. In order to improve survival
rates, clinicians need to be armed with new diagnostic modal-
ities capable of detecting breast cancer at an early stage
before tumour cells spread to regional lymph nodes or distant
sites [26]. Novel cancer biomarkers are expected to open up
a new era in cancer diagnostics and will meet current medical
needs related to early detection, monitoring and prediction of
treatment results in breast cancer patients [27]. To our knowl-
edge, our study is the only one to date showing that the bead
array platform is useful for finding signatures specific for pri-
mary non-metastatic breast cancer and differentiating these
patients from normal subjects using sensitive combinatorial
classifiers. This approach also has potential applications for
early detection of breast cancer. It is notable that analysis of
Figure 2
Classification performance of combinatorial markers identified through 35-plex panel assay Classification performance of combinatorial markers identified through 35-plex panel assay. (a) Principal component analysis (PCA) with 35 markers 
showed clustering and separation of breast cancer patients (closed circle) and normal subjects (open circle) in the PCA chart using principal com-
ponent (Comp) 1 and 2. NF = normal female; BC = breast cancer. (b) The area under the curve was calculated for combinatorial markers and a sin-
gle marker, and compared using a receiver operating curve. CEA = carcinoembryonic antigen; EGF = epidermal growth factor; LDA = linear 
discriminant analysis; RF = random forests; SVM = support vector machine.
Table 3
Diagnostic performance of three classification algorithms using combinatorial markers
Algorithm Marker combination Accuracy (%) Sensitivity
(%)
Specificity
(%)
Train Validation Train Validation Train Validation
RF EGF, sCD40L, HMWK, ApoA1,
PAI-1, DD, VDBP, VN
91.8 93.8 89.8 92.8 93.7 94.7
SVM EGF, sCD40L, HMWK, ApoA1,
PAI-1, DD, VDBP, VN
91.5 88.4 89.5 87.5 93.4 89.3
LDA EGF, sCD40L, HMWK, ApoA1, PAI-1, VDBP 87.6 87.4 84.8 88.4 90.4 86.1
Apo = apolipoprotein; DD = D-dimer; EGF = epidermal growth factor; HMWK = high-molecular-weight kininogen; LDA = linear discriminant 
analysis; PAI-1 = plasminogen activator inhibitor-1; RF = random forests; sCD40L = soluble CD-40 ligand; SVM = support vector machine; 
VDBP = vitamin-D binding protein.Breast Cancer Research    Vol 11 No 2    Kim et al.
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diverse proteins in serum revealed biomarkers correlating with
clinical and pathological variables, including receptor expres-
sion status on the cancer cells. Recently, Carlsson and col-
leagues introduced an scFv-antibody array platform that could
successfully distinguish metastatic breast cancer patients
from normal people [21]. Nolen and colleagues used a multi-
plex bead array platform to profile serum biomarkers predicting
response to neoadjuvant chemotherapy in locally advanced
breast cancer [22]. Thus, in the long term, biomarkers and
array-based technology can practically be used for early
detection of breast cancer and for stratifying patients, deter-
mining their likelihood of experiencing recurrence or having a
drug response, or predicting their survival expectancy [16].
Our study has some limitations. Some of the markers identified
in this study may not be specific for breast cancer and may
possibly reflect a systemic response to tissue damage or
inflammation. Furthermore, the analytes included in this study
are not comprehensive. A variety of other analytes might
behave differentially in the blood of cancer patients. Signature
profiling of other benign breast conditions or systemic dis-
eases and further array panel study using a wider range of
markers will resolve such issues.
Alteration of cytokines and growth factors in breast 
cancer
Among the cytokines and growth factors included in this
study, EGF was the only marker increased in the serum of
breast cancer patients and correlated with advanced T stage.
Up-regulation of other cytokines was not pronounced. High
levels of circulating EGF were reported in serum samples from
HER2-negative breast cancer patients, although increased
levels of IL-8 were consistently noted in serum samples from
metastatic breast cancer patients [21,28,29]. This discordant
result might be caused by differences in the study populations.
In previous studies by Vazquez-martin and colleagues [28] and
Carlsson and colleagues [21], serum samples were taken prin-
cipally from patients with metastasis. However, only 8 of 98
breast cancer patients (8.1%) in this study had metastasis. In
the study by Benoy and colleagues relatively large numbers of
breast cancer patients without metastasis were recruited and
compared with normal control subjects [29]. This difference in
study populations might explain the discordant results across
the studies with regard to IL-8 and EGF levels.
Alteration of coagulation and thrombosis in breast 
cancer
Hypercoagulability is frequently seen in the setting of cancer,
with Trousseau's sign first reported over 100 years ago [30].
Multiple mechanisms are considered contributory to this phe-
nomenon, such as secretion of tissue factor, cancer pro-coag-
ulant, PAI-1, mucin molecules with altered glycan and other
thrombogenic cytokines from cancer cells [31]. The multiplex
array used in this study contained coagulation- and thrombo-
sis-related markers such as sCD40L, HMWK, D-dimer, PAI-1
and free haemoglobin. An assay using this panel revealed
increased concentrations of sCD40L and decreased levels of
HMWK and PAI-1 in breast cancer patients. Roselli and col-
leagues first noted the association between elevated plasma
sCD40L levels in lung cancer; specifically advanced squa-
mous cell carcinoma. They also noted in vivo platelet activa-
tion with this type of tumour [32]. Membrane-bound CD40L, a
precursor of sCD40L, is a transmembrane glycoprotein mainly
expressed by activated T cells and activated platelets [33].
Recently, it has been suggested that activation of the CD40/
CD40L pathway may enhance the pro-coagulant activity of
tumour cells through up-regulation of tissue factor expression
[34]. Thrombin generation and peritumoural fibrin deposition
induced by tissue factor then promote angiogenesis and plate-
let activation [35]. In our study, quantitative changes in serum
HMWK levels were also observed in breast cancer patients.
This is in agreement with a study previous reporting down-reg-
ulation of HMWK in tissue samples from breast cancer
patients [36]. Given the fact that HMWK also has pro-throm-
botic and pro-angiogenic properties through releasing brady-
kinin [37], the behaviour of these two proteins in the serum of
breast cancer patients is consistent with the perceived con-
cept of cancer biology.
Table 4
Comparison of sensitivity of combinatorial markers vs. single marker
Stage I to II Stage III to IV Total cases
Classification method Sensitivity (%) Sensitivity (%) Sensitivity (%)
Algorithm RF 86.3(44/51) 93.6(44/47) 89.8
SVM 90.2(46/51) 93.6(44/47) 91.8
LDA 82.4(42/51) 85.1(40/47) 83.7
Single marker CA15-3* 0 (0/49) 6.4 (3/47) 3.1 (3/96)
TPA* 23.1 (9/39) 29.0 (11/38) 26.0 (20/77)
*Cut-off levels of CA15-3 and TPA were 27 U/ml and 95 U/L, respectively.
CA = cancer antigen; LDA = linear discriminant analysis; RF = random forests; SVM = support vector machine; TPA = tissue polypeptide antigen.Available online http://breast-cancer-research.com/content/11/2/R22
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PAI-1 is frequently up-regulated in cancer cells [31], and ele-
vated PAI-1 has been found to be a poor prognostic marker in
the setting of breast cancer [38]. PAI-1 contributes to cancer
dissemination by preventing excess degradation of the extra-
cellular matrix, modulating cell adhesion [39], promoting
tumour angiogenesis [40] and stimulating proliferation [41].
However, in our study, serum PAI-1 levels were unexpectedly
decreased in breast cancer patients compared with normal
subjects. This may have been due to pre-analytic or analytic
error, in addition to other possibilities. PAI-1 exists in plasma
or serum as a free form, a complex form mostly with vitronectin
and tissue-type plasminogen activator (tPA) or urokinase-type
plasminogen activator (uPA), a latent form and a cleaved form
[42]. One report described different PAI-1 glycosylation pat-
terns, depending on cellular origin [43]. There are currently no
data available concerning changes in amount or concentration
of cleaved or variant glycoforms of PAI-1 in cancer patients.
The specificity of the antibodies used in our study should be
tested, as should qualitative alterations of PAI-1 in cancer that
may affect antigenicity of epitopes.
D-dimer is a marker of ongoing fibrinolysis that is frequently
increased in various cancers [44-46]. Although the difference
in the serum D-dimer concentration between breast cancer
and normal patients did not reach statistical significance in our
study, the mean D-dimer level was higher in breast cancer
Table 5
Clinicopathological comparison of serum biomarkers in breast cancer
Clinicopathological Concentration of biomarkers factors (mean ± SD) P value
T stage T1 to 2 (n = 85) T3 to 4 (n = 13)
A1AT (ng/ml) 4059.69 ± 6175.49 550.85 ± 712.09 0.001
EGF (ng/ml) 265.71 ± 200.59 452.23 ± 221.82 0.017
ApoH (μg/ml) 122.83 ± 30.97 144.18 ± 31.13 0.023
N stage N0 (n = 32) N1 to 3 (n = 66)
sVCAM-1 (ng/ml) 672.13 ± 109.22 755.17 ± 188.23 0.007
Transthyretin (ng/ml) 160.62 ± 55.99 185.54 ± 58.18 0.047
M stage M0 (n = 90) M1 (n = 8)
proApoA1 (μg/ml) 27.38 ± 9.28 19.63 ± 13.41 0.032
ER expression Negative (n = 52) Positive (n = 44)
A2M (μg/ml) 66.73 ± 23.27 82.51 ± 31.51 0.006
Vitronectin (ng/ml) 5458.08 ± 3224.21 4126.95 ± 1508.43 0.012
Transthyretin (ng/ml) 187.61 ± 57.12 162.24 ± 51.31 0.025
HMWK (ng/ml) 16767.50 ± 12263.40 22483.41 ± 14115.87 0.035
PAI-1 (ng/ml) 20.22 ± 7.06 17.51 ± 5.68 0.043
PR expression Negative (n = 34) Positive (n = 62)
A2M (μg/ml) 65.59 ± 19.03 78.56 ± 31.52 0.031
CA19-9 (U/ml) 27.16 ± 19.19 78.89 ± 187.35 0.035
c-erbB2 expression Negative (n = 42) Positive (n = 53)
sVCAM-1 (ng/ml) 770.21 ± 197.73 696.91 ± 143.80 0.047
SAA (ng/ml) 2427.74 ± 250.48 5813.77 ± 11884.32 0.048
A1AT = alpha-1 antitrypsin; A2M = alpha-2 macroglobulin; Apo = apolipoprotein; CA = cancer antigen; EGF = epidermal growth factor; ER = 
oestrogen receptor; HMWK = high-molecular-weight kininogen; PAI = plasminogen activator inhibitor; PR = progesterone receptor; ProApo = 
proapolipoprotein; SAA = serum amyloid A; SD = standard deviation; sVCAM = soluble vascular cell adhesion molecule.Breast Cancer Research    Vol 11 No 2    Kim et al.
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patients, and two algorithms (RF and SVM) selected D-dimer
as a classifier specific for breast cancer. It is also noteworthy
that the serum concentration of D-dimer was correlated with
the number of lymph nodes with tumour metastases in our
sample.
Alterations of adhesion molecules in breast cancer
Soluble variants of cell adhesion molecules (CAMs) are ele-
vated in the blood of patients with inflammation, arthritis, dia-
betes and various cancers [47]. It has been suggested that
soluble forms of these CAMs may play an important role in
cancer cell growth and metastasis by promoting angiogenesis
[48]. As expected based on in vitro results, an in vivo study on
alterations in soluble CAMs in breast cancer showed
increased concentrations of sICAM-1 and sVCAM-1 in the
blood of advanced breast cancer patients, which was corre-
lated with the number of metastases and the number of circu-
lating tumour cells [49]. However, our study showed
somewhat different behaviour on the part of sICAM-1 and
sVCAM-1. The concentration of sVCAM-1 was not increased
(it was even lower in breast cancer patients), and its level did
not covariate with stage or presence of metastasis. There was
no meaningful relationship between serum sICAM-1 levels and
clinicopathological parameters. However, our study was con-
sistent with previous studies in that the serum level of sVCAM-
1 was higher in patients with lymph node metastasis. Before
the interpretation of sCAM data, it was thought that sICAM-1
and sVCAM-1 fluctuated widely throughout the menstrual
cycle (not the menstruation period) to the degree that the
mean difference between the peak and baseline serum levels
was up to 20% [50]. It is possible that this type of factor con-
founded the results in this study. Control of this confounder is
necessary in all studies on soluble CAMs so data can be cor-
rectly interpreted and the exact behaviour of soluble CAMs
can be determined.
Vitronectin is a component of the ECM that is involved in can-
cer cell adhesion and migration through interaction of its
receptor integrin alphavbeta5 or alphavbeta3 [51,52], uroki-
nase-type plasminogen activator receptor (uPAR) complex
[53] and PAI-1 [54]. It has recently been shown that matrix
metalloproteinase (MMP)-2 secreted by tumour cells
degrades vitronectin and produces fragmented vitronectin,
which is more potent than its naïve form in promoting adhesion
and migration of cancer cells [55]. Fragmented vitronectin is
increased in the serum of hepatocellular carcinoma patients,
but mRNA expression of vitronectin is paradoxically decreased
in carcinoma tissue [56]. In our study, only the naïve form was
measured by a pair of capture and detection antibodies used
in the 35-plex panel. Given the perceived role of vitronectin in
cancer, decreased vitronectin levels in serum might be a
reflection of increased turnover rate of vitronectin by tumour
cells.
Alteration of metabolic markers in breast cancer
Proteins related to lipid metabolism are included in the current
array panel. Among these markers, decreased expression of
ApoA1 was notable in cancer serum. ProApoA1 levels were
increased among cancer patients; lower proApoA1 levels
were correlated with the presence of metastasis. Down-regu-
lation of ApoA1 is a consistent finding in serum or tissue in the
setting of several types of cancer [57,58], and our study vali-
dated this phenomenon in the serum of breast cancer patients.
ProApoA1 expression was found to be aberrantly increased in
tissues from breast cancer patients [59]. Our study also con-
firmed up-regulation of this protein in serum. ApoA1 is a major
lipoprotein component of high-density lipoprotein (HDL) and is
also involved in its biogenesis [60]. Recent research on the
relationship between blood lipid profiles and breast cancer
have shown that HDL-cholesterol level is lower in cancer
patients [61], and this decrease is related to up-regulation of
mitogens like oestrogen and higher breast cancer risk, espe-
cially in overweight and obese women [62]. Thus, ApoA1 like
HDL-cholesterol might be a marker reflecting an unfavourable
metabolic environment predisposing to breast cancer. The
biological and clinical implications of these metabolic markers
should be further investigated.
Alterations of carrier proteins in breast cancer
VDBP, macrophage-activating factor and group component-
globulin have diverse biological functions, such as transporta-
tion of vitamin D, actin scavenging, induction of chemotaxis
with C5a and activation of macrophages [63]. The previous
study investigating this protein found that alpha N-acetyl
galactosaminidase, which is increased in the blood of cancer
patients, is secreted by cancer cells and this enzyme strips the
glycosyl moiety of VDBP [64]. The deglycosylated variant
loses its macrophage-activating activity, and this occurrence is
thought to play an important role in the immune suppression
commonly observed in cancer patients. Currently, there are
not enough data related to alterations in blood VDBP levels in
cancer patients to draw any decisive conclusions, and more
information is needed concerning the behaviour of this protein
in the setting of cancer.
Conclusions
This study demonstrated the usefulness of the antibody-bead
array approach in finding signatures that may be specific for
primary non-metastatic breast cancer and illustrated the
potential for early detection of breast cancer. This approach
also revealed serum markers related to clinical and pathologi-
cal features, including receptor expression status in tissue and
provided more general systemic information concerning
responses in breast cancer patients. Further validation is
required before the multiplex bead array approach is routinely
used for screening, monitoring, prediction and prognosis pur-
poses.Available online http://breast-cancer-research.com/content/11/2/R22
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